Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 54

recruiting
3 987
countries
28
conditions
2 109

761 trials match your criteria

Neoplasm malignant

Not recruiting

Study on the Safety and Anti-tumor Effects of GEN1042 Alone or with Pembrolizumab and Chemotherapy in Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Primary amyloidosis

Not recruiting

Study on Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Systemic AL Amyloidosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Eosinophilic oesophagitis

Not recruiting

Study on Tezepelumab for Symptom Relief in Patients Aged 12-80 with Eosinophilic Esophagitis

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezepelumab

Non-small cell lung cancer metastatic

Not recruiting

Study on the Effectiveness and Safety of Atezolizumab and Drug Combination for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Plasma cell myeloma

Not recruiting

Study on the Effectiveness and Safety of Cevostamab and Tocilizumab for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cevostamab

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Daratumumab, and Pomalidomide with Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab

Myelofibrosis

Not recruiting

Study on Extended Access to Momelotinib for Patients with Myelofibrosis

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate

Ovarian cancer recurrent

Not recruiting

Study on ADP-A2M4CD8 and Nivolumab for Patients with Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab

Neoplasm

Not recruiting

Study on CTL-002 and Nivolumab for Patients with Advanced-Stage, Relapsed/Refractory Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab

Breast cancer metastatic

Not recruiting

Study of inavolisib, palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant

Small cell lung cancer

Not recruiting

Study of Lurbinectedin Alone or with Irinotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Irinotecan

Plasma cell myeloma

Not recruiting

Study on Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed, Refractory, or Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.